BMAL1 and central nervous system cancer: Enhanced 1A-116 efficacy was reported at low-level expression of Bmal1 in GBM cells and a differential overall survival was observed when applying 1A-116 at Zeitgeber times 12 (ZT 12) to nude mouse models with gliomas (Trebucq et al., 2021).